High-intensity interval training combined with moderate-intensity continuous training in post-PCI acute myocardial infarction patients: A randomized controlled trial.

Am Heart JMay 8, 2026 (epub)
Clinical ResearchCardiology

Weilin Wang, Yingchun Gu, Dongwei Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy and safety of combined high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) in 204 post-PCI acute myocardial infarction patients. The study found that combined training significantly improved peak oxygen consumption (VO2 peak) by 5.6 ± 2.3 mL/kg/min compared to MICT alone (2.7 ± 1.9 mL/kg/min, P < .001) and HIIT alone (4.2 ± 1.8 mL/kg/min, P = .003).

Key findings

  • Combined training improved VO2 peak by 5.6 ± 2.3 mL/kg/min compared to MICT alone (2.7 ± 1.9 mL/kg/min, P < .001).
  • 76.7% of patients in the combined training group achieved a clinically meaningful improvement in VO2 peak (≥3 mL/kg/min).
  • Left ventricular ejection fraction (LVEF) increased by 8.6 ± 3.2% in the combined training group.
  • The incidence of major adverse cardiovascular events (MACE) was low at 2.9%, with no significant inter-group differences (P = .85).

Why it matters

This study highlights the potential of combined HIIT and MICT training to enhance cardiopulmonary function and cardiac remodeling in post-PCI AMI patients, suggesting a more effective rehabilitation strategy that may improve patient outcomes.

Source

Published in Am Heart J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.